Chemicon and RheoGene sign license to use RheoSwitch and related technologies within Chemicon's research product lines focused on specialty research markets, including stem cell biology portfolio
Through this agreement, Chemicon accesses the innovative RheoSwitch technology that regulates the timing and level of gene expression in all types of eucaryotic cells through the interaction of RheoGene's proprietary ecdysone-based receptors and proprietary small molecule ligands, which will be supplied under the agreement.
Chemicon will apply this technology both to generic cloning and expression reagents and to important genes involved in cell differentiation and development.
"Chemicon is looking forward to adding the RheoSwitch technology to our product development capabilities," said Jeffrey Linton, president of Chemicon.
"The new products that will be developed with this technology will greatly enhance our expanding portfolio of innovative tools for stem cell research".
"We are pleased to bring RheoSwitch gene regulation technology into Chemicon's research products and services business," said Thomas Tillett, RheoGene president and CEO.
"RheoSwitch technology will enable Chemicon to provide its customers with a broad range of proprietary cell-based gene regulation products in their specialty research markets.
"We are excited about the potential for Chemicon to add RheoSwitch products for regulated gene expression and directed differentiation in pleuripotent and somatic stem cells to its rapidly growing stem cell biology portfolio".
This licensing agreement reflects the alignment of both organizations in their objectives to enhance the growth of their respective technology positions in the stem cell field by offering high quality products and services that advance the state of the art in their respective business sectors, Chemicon in bringing high-value specialty products to the research market, and RheoGene in developing regulated stem cell-based therapies for treatment of human diseases.
